title: Mice deficient in MIM expression are predisposed to lymphomagenesis.
abstract: Missing in metastasis (MIM) is a member of newly emerged inverse Bin-Amphiphysin-Rvs (BAR) domain protein family and a putative metastasis suppressor. Although reduced MIM expression has been associated with bladder, breast and gastric cancers, evidence for the role of MIM in tumor progression remains scarce and controversial. Herein we characterized a MIM knockout mouse strain and observed that MIM-deficient mice often developed enlarged spleens. Autopsy and histological analysis revealed that nearly 78% of MIM(-/-) mice developed tumors with features similar to diffuse large B lymphoma during a period from 1 to 2 years. MIM(-/-) mice also exhibited abnormal distribution of B cells in lymphoid organs with decrease in the spleen but increase in the bone marrow and the peripheral blood. Furthermore, the bone marrow of MIM(-/-) mice contained a higher percentage of pre-B2 cells but fewer immature B-cells than wild-type mice. In response to CXCL13, a B-cell chemokine released from splenic stromal cells, MIM-deficient B-cells did not undergo chemotaxis or morphological changes in response to the chemokine and also did not internalize CXCR5, the receptor of CXCL13. Microarray analyses demonstrated that MIM is the only member of the I-BAR domain family that was highly expressed in human B cells. However, low or absent MIM expression was common in either primary B-cell malignancies or established B-cell acute lymphocytic leukemia or lymphomas. Thus, our data demonstrate for the first time an important role for MIM in B-cell development and suggest that predisposition of MIM-null mice to lymphomagenesis may involve aberrant interactions between B lineage cells and the lymphoid microenvironment.
authors.affiliation: Center for Vascular and Inflammatory Diseases, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
authors.forename: D
authors.initials: D
authors.lastname: Yu
authors.forename: X H
authors.initials: XH
authors.lastname: Zhan
authors.forename: X F
authors.initials: XF
authors.lastname: Zhao
authors.forename: M S
authors.initials: MS
authors.lastname: Williams
authors.forename: G B
authors.initials: GB
authors.lastname: Carey
authors.forename: E
authors.initials: E
authors.lastname: Smith
authors.forename: D
authors.initials: D
authors.lastname: Scott
authors.forename: J
authors.initials: J
authors.lastname: Zhu
authors.forename: Y
authors.initials: Y
authors.lastname: Guo
authors.forename: S
authors.initials: S
authors.lastname: Cherukuri
authors.forename: C I
authors.initials: CI
authors.lastname: Civin
authors.forename: X
authors.initials: X
authors.lastname: Zhan
mesh_terms: D000818:Animals; D001402:B-Lymphocytes / Q000187:drug effects / Q000378:metabolism; D001853:Bone Marrow / Q000378:metabolism; D002471:Cell Transformation, Neoplastic / Q000235:genetics*; D002478:Cells, Cultured; D054382:Chemokine CXCL13 / Q000494:pharmacology; D002633:Chemotaxis / Q000187:drug effects; D005260:Female; D020022:Genetic Predisposition to Disease; D006098:Granulocytes / Q000378:metabolism; D006801:Humans; D007963:Leukocytes, Mononuclear / Q000378:metabolism; D016403:Lymphoma, Large B-Cell, Diffuse / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D008297:Male; D051379:Mice; D018345:Mice, Knockout; D008840:Microfilament Proteins / Q000235:genetics* / Q000378:metabolism; D009363:Neoplasm Proteins / Q000235:genetics* / Q000378:metabolism; D054380:Receptors, CXCR5 / Q000378:metabolism; D013154:Spleen / Q000378:metabolism / Q000473:pathology; D013601:T-Lymphocytes / Q000378:metabolism
chemical_list: C513179:CXCR5 protein, mouse; D054382:Chemokine CXCL13; C486386:Cxcl13 protein, mouse; D008840:Microfilament Proteins; C473219:Mtss1 protein, mouse; D009363:Neoplasm Proteins; D054380:Receptors, CXCR5
references.citation: Cell Cycle. 2010 Jul 1;9(13):2522-8
references.pmid: 20581461
references.citation: Nat Med. 2007 Aug;13(8):944-51
references.pmid: 17632527
references.citation: Cancer Microenviron. 2008 Dec;1(1):1-11
references.pmid: 19308680
references.citation: Structure. 2007 Feb;15(2):145-55
references.pmid: 17292833
references.citation: Mol Cancer Ther. 2005 Dec;4(12):1867-79
references.pmid: 16373702
references.citation: Cancer Res. 2008 Feb 15;68(4):961-4
references.pmid: 18281468
references.citation: Curr Opin Oncol. 2010 Sep;22(5):424-30
references.pmid: 20679770
references.citation: J Cell Biochem. 2007 Nov 1;102(4):829-39
references.pmid: 17914743
references.citation: J Gastrointest Surg. 2011 Jul;15(7):1205-12
references.pmid: 21562916
references.citation: Nat Rev Immunol. 2002 Dec;2(12):920-32
references.pmid: 12461565
references.citation: Development. 2010 Apr;137(7):1075-84
references.pmid: 20181743
references.citation: EMBO J. 2005 Jan 26;24(2):240-50
references.pmid: 15635447
references.citation: BMC Cancer. 2010 Aug 15;10:428
references.pmid: 20712855
references.citation: Dev Cell. 2010 Jun 15;18(6):884-901
references.pmid: 20627072
references.citation: Cancer Lett. 2004 Nov 25;215(2):209-20
references.pmid: 15488640
references.citation: Oncogene. 2012 Jul 26;31(30):3561-8
references.pmid: 22081072
references.citation: Genes Dev. 2004 Nov 15;18(22):2724-9
references.pmid: 15545630
references.citation: Eur J Cancer. 2009 Jun;45(9):1673-83
references.pmid: 19328678
references.citation: J Clin Oncol. 2010 Sep 10;28(26):4022-8
references.pmid: 20644094
references.citation: Trends Cell Biol. 2008 Feb;18(2):52-60
references.pmid: 18215522
references.citation: Cell. 2009 Apr 17;137(2):191-6
references.pmid: 19379681
references.citation: Nat Immunol. 2004 Jan;5(1):12-4
references.pmid: 14699400
references.citation: J Cell Sci. 2011 Apr 15;124(Pt 8):1245-55
references.pmid: 21406566
references.citation: Neoplasia. 2002 Jul-Aug;4(4):291-4
references.pmid: 12082544
references.citation: Blood. 2002 Jul 1;100(1):246-58
references.pmid: 12070034
references.citation: J Cell Sci. 2005 Nov 15;118(Pt 22):5393-403
references.pmid: 16280553
references.citation: Cancer Cell. 2003 Nov;4(5):349-60
references.pmid: 14667502
references.citation: Breast Dis. 2006-2007;26:75-85
references.pmid: 17473367
references.citation: EMBO J. 1992 May;11(5):1891-9
references.pmid: 1582417
references.citation: Oncogene. 2010 Dec 9;29(49):6464-74
references.pmid: 20802524
references.citation: Blood. 2009 Sep 10;114(11):2280-9
references.pmid: 19608748
references.citation: Int J Oncol. 2005 Jun;26(6):1699-705
references.pmid: 15870888
references.citation: Blood. 2008 Sep 1;112(5):1570-80
references.pmid: 18725575
references.citation: Oncogene. 2005 Mar 17;24(12):2059-66
references.pmid: 15688017
references.citation: J Cell Biol. 2007 Mar 26;176(7):953-64
references.pmid: 17371834
references.citation: J Pathol. 2007 Sep;213(1):46-55
references.pmid: 17668415
references.citation: Biochem J. 2003 Apr 15;371(Pt 2):463-71
references.pmid: 12570871
references.citation: Hum Pathol. 2007 Aug;38(8):1201-6
references.pmid: 17442377
references.citation: Cancer Invest. 2007 Mar;25(2):79-86
references.pmid: 17453818
references.citation: Development. 2011 May;138(10):2035-47
references.pmid: 21471152
references.citation: Biochem Soc Symp. 2005;(72):223-31
references.pmid: 15649145